Boehringer Ingelheim’s Expands and Upgrades its Production Site in Koropi, Greece

In a strategic move to fortify its global presence and enhance pharmaceutical production capabilities, Boehringer Ingelheim, the pharmaceutical giant, has announced the further expansion and upgrade of its production site…

Continue ReadingBoehringer Ingelheim’s Expands and Upgrades its Production Site in Koropi, Greece

GSK and Tempus Forge Ahead: A Pioneering Collaboration in Precision Medicine to Propel R&D

In a significant stride towards advancing precision medicine, GlaxoSmithKline (GSK) has announced a three-year collaboration agreement with Tempus, a leader in data-driven precision medicine, to get access to Tempus’ AI-enable…

Continue ReadingGSK and Tempus Forge Ahead: A Pioneering Collaboration in Precision Medicine to Propel R&D

Gradalis’ GRAD1405 bi-shRNAi Breakthrough: A Triumphant Stride Against Drug-Resistant Cancers

In a significant leap forward in the ongoing battle against drug-resistant cancers, Gradalis, a forefront player in personalized cancer immunotherapy, has unveiled promising results for its innovative candidate, GRAD1405 bi-shRNAi.…

Continue ReadingGradalis’ GRAD1405 bi-shRNAi Breakthrough: A Triumphant Stride Against Drug-Resistant Cancers
Read more about the article Pioneering the Future: European Medicines Agency and Heads of Medicines Agencies Unveil AI Workplan
FILE PHOTO: The exterior of EMA, European Medicines Agency is seen in Amsterdam, Netherlands December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo

Pioneering the Future: European Medicines Agency and Heads of Medicines Agencies Unveil AI Workplan

A Strategic Roadmap to Harness the Power of Artificial Intelligence in Medicines Regulation In a bold leap towards innovation, the European Medicines Agency (EMA) and the Heads of Medicines Agencies…

Continue ReadingPioneering the Future: European Medicines Agency and Heads of Medicines Agencies Unveil AI Workplan

AstraZeneca and Absci Join Forces in a $247 Million Deal to Combat Cancer with Innovative Antibody Design

In a groundbreaking move to advance cancer therapeutics, AstraZeneca, a global pharmaceutical giant, has recently entered into a strategic collaboration with Absci, a leading synthetic biology company. The deal, valued…

Continue ReadingAstraZeneca and Absci Join Forces in a $247 Million Deal to Combat Cancer with Innovative Antibody Design

Major Milestone: FDA Grants Approval to Vertex and CRISPR Therapeutics for CASGEVY™ in the Treatment of Sickle Cell Disease

Groundbreaking Gene-Editing Therapy Receives Green Light, Signaling a New Era in Sickle Cell Treatment Date: 12 December 2023 Introduction: In a landmark decision, the U.S. Food and Drug Administration (FDA)…

Continue ReadingMajor Milestone: FDA Grants Approval to Vertex and CRISPR Therapeutics for CASGEVY™ in the Treatment of Sickle Cell Disease

Revolutionizing Treatment: UK Grants Authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for Groundbreaking CRISPR/Cas9 Gene-Edited Therapy

MHRA Approves CASGEVY™ for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, Marking a Milestone in Precision Medicine Date: 7 December 2023 Introduction: In a historic move that signals a new…

Continue ReadingRevolutionizing Treatment: UK Grants Authorization to Vertex Pharmaceuticals and CRISPR Therapeutics for Groundbreaking CRISPR/Cas9 Gene-Edited Therapy